Finance

HIV test maker reports loss of $0.11 per share

Published in AIDS Weekly, December 15th, 2003

Calypte Biomedical Corporation (CYPT), the developer and marketer of the only two U.S. Food and Drug Administration (FDA) approved HIV-1 antibody tests for use with urine samples, announced financial results for the third quarter and 9-months ended September 30, 2003.

Revenues for the quarter totaled $897,000, versus revenues of $493,000 for the comparable period in 2002 and $749,000 for the previous quarter ended June 30, 2003. The net loss attributable to common stockholders for the quarter was $7.3 million, or $0.11 per common share, compared to a net loss of $1.5 million, or $0.51 per common share for the 3 months ended September 30, 2002.

The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-12-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry